Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ovarian Neoplasms | 72 | 2024 | 4919 | 8.200 |
Why?
|
Endometrial Neoplasms | 13 | 2023 | 1386 | 2.890 |
Why?
|
Cystadenocarcinoma, Serous | 11 | 2022 | 480 | 2.710 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 28 | 2023 | 11886 | 1.790 |
Why?
|
Neoplasms, Glandular and Epithelial | 8 | 2015 | 489 | 1.770 |
Why?
|
BRCA2 Protein | 14 | 2023 | 803 | 1.730 |
Why?
|
BRCA1 Protein | 21 | 2024 | 1156 | 1.730 |
Why?
|
Genes, BRCA1 | 10 | 2022 | 756 | 1.710 |
Why?
|
Phthalazines | 11 | 2022 | 397 | 1.650 |
Why?
|
Genes, BRCA2 | 9 | 2022 | 593 | 1.600 |
Why?
|
DNA Polymerase II | 4 | 2019 | 104 | 1.590 |
Why?
|
Antineoplastic Agents | 29 | 2023 | 13698 | 1.470 |
Why?
|
Fallopian Tube Neoplasms | 6 | 2018 | 329 | 1.440 |
Why?
|
Platinum | 6 | 2023 | 222 | 1.290 |
Why?
|
DNA Repair | 13 | 2023 | 2054 | 1.230 |
Why?
|
Peritoneal Neoplasms | 7 | 2024 | 714 | 1.230 |
Why?
|
Neoplasm Recurrence, Local | 21 | 2023 | 9442 | 1.160 |
Why?
|
Drug Resistance, Neoplasm | 20 | 2021 | 5342 | 1.130 |
Why?
|
Isoxazoles | 3 | 2024 | 233 | 1.130 |
Why?
|
Poly(ADP-ribose) Polymerases | 5 | 2018 | 428 | 1.120 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 3 | 2016 | 1105 | 1.010 |
Why?
|
Pyrazines | 5 | 2024 | 1206 | 0.970 |
Why?
|
Cell Cycle Proteins | 3 | 2022 | 3450 | 0.960 |
Why?
|
Carcinoma, Endometrioid | 2 | 2018 | 277 | 0.880 |
Why?
|
Deoxycytidine | 4 | 2024 | 888 | 0.860 |
Why?
|
Uterine Neoplasms | 3 | 2021 | 1424 | 0.860 |
Why?
|
Germ-Line Mutation | 6 | 2022 | 1887 | 0.860 |
Why?
|
DNA Replication | 8 | 2022 | 1428 | 0.850 |
Why?
|
Microsatellite Instability | 3 | 2023 | 726 | 0.820 |
Why?
|
DNA Damage | 10 | 2022 | 2472 | 0.770 |
Why?
|
DNA Mismatch Repair | 3 | 2023 | 432 | 0.730 |
Why?
|
Histone Deacetylase Inhibitors | 4 | 2014 | 778 | 0.700 |
Why?
|
Piperazines | 8 | 2022 | 2553 | 0.670 |
Why?
|
Indazoles | 5 | 2023 | 306 | 0.650 |
Why?
|
Pyrimidinones | 2 | 2021 | 386 | 0.640 |
Why?
|
Female | 115 | 2024 | 397515 | 0.630 |
Why?
|
Adenocarcinoma, Clear Cell | 2 | 2018 | 218 | 0.620 |
Why?
|
Enzyme Inhibitors | 9 | 2023 | 3726 | 0.590 |
Why?
|
Mutation | 23 | 2023 | 30266 | 0.590 |
Why?
|
Oligonucleotide Array Sequence Analysis | 5 | 2012 | 3810 | 0.590 |
Why?
|
MicroRNAs | 8 | 2023 | 3811 | 0.570 |
Why?
|
Transcription Factor AP-1 | 4 | 2007 | 321 | 0.550 |
Why?
|
Humans | 158 | 2024 | 768970 | 0.540 |
Why?
|
Anilides | 2 | 2022 | 414 | 0.520 |
Why?
|
Genetic Testing | 6 | 2022 | 3591 | 0.510 |
Why?
|
Benzoquinones | 2 | 2014 | 198 | 0.500 |
Why?
|
Cyclooxygenase Inhibitors | 2 | 2008 | 361 | 0.480 |
Why?
|
Neoplasms | 16 | 2022 | 22389 | 0.480 |
Why?
|
Pyrazoles | 4 | 2021 | 2029 | 0.470 |
Why?
|
Colonic Neoplasms | 5 | 2007 | 2543 | 0.470 |
Why?
|
Lactams, Macrocyclic | 2 | 2014 | 319 | 0.460 |
Why?
|
Salvage Therapy | 1 | 2020 | 1277 | 0.430 |
Why?
|
DNA Breaks, Double-Stranded | 6 | 2024 | 608 | 0.410 |
Why?
|
Thiazoles | 2 | 2022 | 1542 | 0.410 |
Why?
|
Kidney Failure, Chronic | 3 | 2009 | 2493 | 0.400 |
Why?
|
Neoadjuvant Therapy | 3 | 2022 | 2909 | 0.400 |
Why?
|
Carboplatin | 7 | 2023 | 799 | 0.390 |
Why?
|
Cyclooxygenase 2 | 4 | 2007 | 597 | 0.390 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2021 | 2433 | 0.380 |
Why?
|
Gene Expression Profiling | 9 | 2021 | 9549 | 0.380 |
Why?
|
Hydroxamic Acids | 1 | 2014 | 483 | 0.370 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2009 | 3253 | 0.360 |
Why?
|
Antibodies, Monoclonal | 5 | 2023 | 9264 | 0.350 |
Why?
|
Protein Kinase Inhibitors | 4 | 2024 | 5707 | 0.350 |
Why?
|
Protein Prenylation | 2 | 2007 | 70 | 0.350 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2014 | 388 | 0.350 |
Why?
|
NF-kappa B | 3 | 2007 | 2492 | 0.330 |
Why?
|
Adenocarcinoma | 6 | 2019 | 6401 | 0.310 |
Why?
|
Carcinoma | 3 | 2019 | 2340 | 0.310 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2011 | 379 | 0.310 |
Why?
|
Cisplatin | 6 | 2018 | 1661 | 0.300 |
Why?
|
Disease-Free Survival | 12 | 2023 | 6856 | 0.300 |
Why?
|
Genomic Instability | 6 | 2018 | 715 | 0.300 |
Why?
|
Breast Neoplasms | 10 | 2022 | 21188 | 0.290 |
Why?
|
Molecular Biology | 2 | 2008 | 573 | 0.290 |
Why?
|
Signal Transduction | 17 | 2024 | 23653 | 0.290 |
Why?
|
Fluorobenzenes | 1 | 2009 | 179 | 0.290 |
Why?
|
Piperidines | 4 | 2020 | 1667 | 0.280 |
Why?
|
Pyridines | 2 | 2022 | 2895 | 0.280 |
Why?
|
Aged | 37 | 2024 | 171786 | 0.280 |
Why?
|
Receptors, Estrogen | 4 | 2022 | 2252 | 0.280 |
Why?
|
rab5 GTP-Binding Proteins | 1 | 2007 | 47 | 0.280 |
Why?
|
Cell Line, Tumor | 18 | 2024 | 17173 | 0.280 |
Why?
|
Mevalonic Acid | 1 | 2006 | 46 | 0.270 |
Why?
|
Membrane Proteins | 6 | 2024 | 7885 | 0.270 |
Why?
|
Drug Synergism | 4 | 2019 | 1762 | 0.270 |
Why?
|
Neoplasm Proteins | 6 | 2020 | 3608 | 0.270 |
Why?
|
Atovaquone | 1 | 2006 | 56 | 0.270 |
Why?
|
Platinum Compounds | 2 | 2021 | 95 | 0.270 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 2 | 2020 | 196 | 0.260 |
Why?
|
PPAR gamma | 2 | 2006 | 487 | 0.260 |
Why?
|
Ligands | 3 | 2022 | 3283 | 0.260 |
Why?
|
Ribose | 2 | 2022 | 63 | 0.260 |
Why?
|
Metalloendopeptidases | 1 | 2007 | 386 | 0.260 |
Why?
|
Rifabutin | 1 | 2005 | 59 | 0.250 |
Why?
|
Middle Aged | 40 | 2024 | 223737 | 0.250 |
Why?
|
Erythropoietin | 2 | 2007 | 718 | 0.250 |
Why?
|
Depsipeptides | 1 | 2006 | 96 | 0.250 |
Why?
|
Microarray Analysis | 1 | 2008 | 755 | 0.250 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2007 | 751 | 0.240 |
Why?
|
Mutation, Missense | 1 | 2014 | 2592 | 0.240 |
Why?
|
Babesiosis | 1 | 2006 | 92 | 0.240 |
Why?
|
Aspirin | 2 | 2008 | 3135 | 0.240 |
Why?
|
Thiazolidinediones | 1 | 2008 | 461 | 0.240 |
Why?
|
Aged, 80 and over | 18 | 2021 | 59739 | 0.240 |
Why?
|
Azithromycin | 1 | 2006 | 201 | 0.240 |
Why?
|
Clinical Trials as Topic | 6 | 2022 | 8055 | 0.230 |
Why?
|
Splenectomy | 1 | 2006 | 392 | 0.230 |
Why?
|
Hematinics | 1 | 2007 | 282 | 0.230 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 318 | 0.230 |
Why?
|
Neoplasm Staging | 10 | 2021 | 11262 | 0.230 |
Why?
|
Protease Inhibitors | 1 | 2007 | 752 | 0.230 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 5434 | 0.220 |
Why?
|
Vasculitis, Central Nervous System | 1 | 2004 | 45 | 0.220 |
Why?
|
Databases, Genetic | 1 | 2011 | 1758 | 0.220 |
Why?
|
Paraproteinemias | 1 | 2006 | 252 | 0.220 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2023 | 878 | 0.220 |
Why?
|
Paclitaxel | 4 | 2022 | 1735 | 0.220 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2022 | 3554 | 0.220 |
Why?
|
Ethics, Medical | 1 | 2008 | 785 | 0.220 |
Why?
|
Treatment Outcome | 17 | 2023 | 65480 | 0.220 |
Why?
|
Erythropoiesis | 1 | 2007 | 693 | 0.220 |
Why?
|
Gene Expression Regulation, Neoplastic | 12 | 2020 | 8664 | 0.210 |
Why?
|
Drug Discovery | 1 | 2011 | 1068 | 0.210 |
Why?
|
ras Proteins | 2 | 2012 | 1058 | 0.210 |
Why?
|
Histones | 3 | 2017 | 2603 | 0.210 |
Why?
|
HSP90 Heat-Shock Proteins | 2 | 2021 | 423 | 0.210 |
Why?
|
Ovary | 4 | 2020 | 965 | 0.210 |
Why?
|
Drug Administration Schedule | 6 | 2020 | 4862 | 0.210 |
Why?
|
Genital Neoplasms, Female | 3 | 2024 | 538 | 0.210 |
Why?
|
Pyrimidines | 2 | 2018 | 3048 | 0.200 |
Why?
|
Lung Neoplasms | 5 | 2023 | 13594 | 0.200 |
Why?
|
Diphosphates | 1 | 2022 | 89 | 0.200 |
Why?
|
Neoplasms, Experimental | 1 | 2007 | 1231 | 0.200 |
Why?
|
Diabetes Complications | 1 | 2009 | 1320 | 0.200 |
Why?
|
Nucleotidyltransferases | 1 | 2024 | 242 | 0.200 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2016 | 2893 | 0.200 |
Why?
|
Organoplatinum Compounds | 2 | 2016 | 408 | 0.200 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2006 | 682 | 0.200 |
Why?
|
CD8-Positive T-Lymphocytes | 6 | 2024 | 4651 | 0.190 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 1 | 2006 | 246 | 0.190 |
Why?
|
Bayes Theorem | 1 | 2010 | 2360 | 0.190 |
Why?
|
Animals | 30 | 2024 | 169335 | 0.190 |
Why?
|
Respiratory Mucosa | 4 | 2010 | 439 | 0.190 |
Why?
|
Endodermal Sinus Tumor | 1 | 2022 | 53 | 0.190 |
Why?
|
Prednisone | 1 | 2006 | 1567 | 0.190 |
Why?
|
Puerperal Disorders | 1 | 2004 | 304 | 0.190 |
Why?
|
Immunohistochemistry | 10 | 2020 | 11116 | 0.190 |
Why?
|
Cell Transformation, Neoplastic | 6 | 2016 | 2848 | 0.190 |
Why?
|
Cyclodextrins | 1 | 2021 | 63 | 0.190 |
Why?
|
Tumor Microenvironment | 4 | 2023 | 3952 | 0.190 |
Why?
|
Dyslipidemias | 1 | 2008 | 873 | 0.180 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2021 | 101 | 0.180 |
Why?
|
Prognosis | 16 | 2022 | 30046 | 0.180 |
Why?
|
Rad51 Recombinase | 3 | 2020 | 191 | 0.180 |
Why?
|
Protein Processing, Post-Translational | 2 | 2007 | 1966 | 0.170 |
Why?
|
Tumor Cells, Cultured | 4 | 2016 | 6131 | 0.170 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2006 | 1320 | 0.170 |
Why?
|
Anti-Inflammatory Agents | 2 | 2007 | 1811 | 0.170 |
Why?
|
Germ Cells | 2 | 2023 | 644 | 0.170 |
Why?
|
Cystadenoma, Serous | 1 | 2020 | 100 | 0.170 |
Why?
|
Renal Dialysis | 1 | 2009 | 1789 | 0.170 |
Why?
|
CA-125 Antigen | 1 | 2022 | 281 | 0.170 |
Why?
|
Sulfonamides | 1 | 2009 | 1981 | 0.160 |
Why?
|
Neutropenia | 2 | 2023 | 893 | 0.160 |
Why?
|
Interferon-alpha | 1 | 2003 | 910 | 0.160 |
Why?
|
DNA Mutational Analysis | 3 | 2020 | 4124 | 0.160 |
Why?
|
Ascites | 2 | 2020 | 338 | 0.160 |
Why?
|
Antimalarials | 1 | 2006 | 909 | 0.160 |
Why?
|
Vulvar Neoplasms | 1 | 2022 | 266 | 0.160 |
Why?
|
Colon | 2 | 2007 | 1803 | 0.160 |
Why?
|
Adult | 29 | 2024 | 223851 | 0.160 |
Why?
|
Anemia | 2 | 2013 | 1517 | 0.160 |
Why?
|
Down-Regulation | 3 | 2018 | 2942 | 0.160 |
Why?
|
Health Status Disparities | 2 | 2021 | 1886 | 0.160 |
Why?
|
Cytoplasmic Dyneins | 1 | 2018 | 24 | 0.160 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2021 | 10400 | 0.160 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2022 | 2884 | 0.160 |
Why?
|
Sarcoma | 1 | 2010 | 1806 | 0.160 |
Why?
|
Respiratory Tract Neoplasms | 2 | 2010 | 56 | 0.160 |
Why?
|
Survival Rate | 7 | 2020 | 12873 | 0.160 |
Why?
|
Tuberous Sclerosis | 1 | 2007 | 1042 | 0.160 |
Why?
|
Single-Cell Analysis | 2 | 2020 | 2542 | 0.150 |
Why?
|
Phenylenediamines | 1 | 2018 | 89 | 0.150 |
Why?
|
Leukocytes, Mononuclear | 2 | 2022 | 1855 | 0.150 |
Why?
|
Radiation Injuries | 2 | 2017 | 1203 | 0.150 |
Why?
|
DNA | 4 | 2023 | 7214 | 0.150 |
Why?
|
Antigens, Neoplasm | 2 | 2016 | 2001 | 0.150 |
Why?
|
CDC2 Protein Kinase | 1 | 2018 | 212 | 0.150 |
Why?
|
Camptothecin | 1 | 2021 | 600 | 0.140 |
Why?
|
Cardiovascular Diseases | 3 | 2009 | 15661 | 0.140 |
Why?
|
Uterine Cervical Neoplasms | 2 | 2020 | 2044 | 0.140 |
Why?
|
DNA, Neoplasm | 2 | 2014 | 1748 | 0.140 |
Why?
|
Multicenter Studies as Topic | 1 | 2022 | 1737 | 0.140 |
Why?
|
Receptor, erbB-2 | 3 | 2022 | 2606 | 0.140 |
Why?
|
Drug Therapy, Combination | 2 | 2020 | 6320 | 0.140 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2019 | 296 | 0.140 |
Why?
|
Gene Fusion | 1 | 2019 | 357 | 0.140 |
Why?
|
Genome, Human | 3 | 2019 | 4456 | 0.130 |
Why?
|
Tumor Suppressor Proteins | 1 | 2007 | 2812 | 0.130 |
Why?
|
Serum | 1 | 2017 | 207 | 0.130 |
Why?
|
Maximum Tolerated Dose | 1 | 2019 | 899 | 0.130 |
Why?
|
Interferons | 1 | 2020 | 720 | 0.130 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2008 | 2763 | 0.130 |
Why?
|
Stomach Neoplasms | 3 | 2019 | 1483 | 0.130 |
Why?
|
Genetic Counseling | 1 | 2020 | 634 | 0.130 |
Why?
|
Biomedical Research | 2 | 2008 | 3463 | 0.130 |
Why?
|
Oncogenes | 1 | 2021 | 1236 | 0.130 |
Why?
|
Doxorubicin | 2 | 2020 | 2234 | 0.130 |
Why?
|
Feasibility Studies | 2 | 2024 | 5323 | 0.130 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 2276 | 0.120 |
Why?
|
Mullerian Ducts | 1 | 2016 | 203 | 0.120 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 906 | 0.120 |
Why?
|
Gene Amplification | 1 | 2020 | 1099 | 0.120 |
Why?
|
Hypoglycemic Agents | 1 | 2008 | 3110 | 0.120 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2018 | 664 | 0.120 |
Why?
|
Telemedicine | 2 | 2024 | 3110 | 0.120 |
Why?
|
Reproductive History | 1 | 2016 | 210 | 0.120 |
Why?
|
Gene Deletion | 3 | 2022 | 2674 | 0.120 |
Why?
|
Endonucleases | 1 | 2017 | 371 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2018 | 725 | 0.120 |
Why?
|
Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2015 | 116 | 0.120 |
Why?
|
Loss of Heterozygosity | 2 | 2014 | 663 | 0.110 |
Why?
|
Pancreatic Neoplasms | 2 | 2024 | 5443 | 0.110 |
Why?
|
Ribonucleoside Diphosphate Reductase | 1 | 2013 | 31 | 0.110 |
Why?
|
Chromatin | 1 | 2006 | 2981 | 0.110 |
Why?
|
Kaplan-Meier Estimate | 5 | 2019 | 6547 | 0.110 |
Why?
|
Drug Monitoring | 1 | 2020 | 965 | 0.110 |
Why?
|
Infusions, Intravenous | 2 | 2020 | 2231 | 0.110 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2020 | 10765 | 0.110 |
Why?
|
Conserved Sequence | 1 | 2017 | 1162 | 0.110 |
Why?
|
Transcription Factors | 3 | 2018 | 12174 | 0.110 |
Why?
|
Urinary Bladder Neoplasms | 3 | 2011 | 2251 | 0.110 |
Why?
|
Injections, Intraperitoneal | 1 | 2014 | 412 | 0.110 |
Why?
|
Models, Genetic | 3 | 2014 | 3449 | 0.110 |
Why?
|
STAT Transcription Factors | 2 | 2020 | 189 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2018 | 998 | 0.110 |
Why?
|
Melanoma | 3 | 2013 | 5709 | 0.110 |
Why?
|
G1 Phase | 1 | 2014 | 403 | 0.100 |
Why?
|
Immunity | 1 | 2018 | 1003 | 0.100 |
Why?
|
Immunoenzyme Techniques | 2 | 2014 | 1705 | 0.100 |
Why?
|
Up-Regulation | 1 | 2021 | 4148 | 0.100 |
Why?
|
Tissue Array Analysis | 1 | 2014 | 551 | 0.100 |
Why?
|
Skin Neoplasms | 3 | 2013 | 5864 | 0.100 |
Why?
|
Neoplasms, Connective and Soft Tissue | 1 | 2012 | 34 | 0.100 |
Why?
|
Organoids | 1 | 2018 | 745 | 0.100 |
Why?
|
Quality of Life | 2 | 2024 | 13510 | 0.100 |
Why?
|
Intestinal Mucosa | 1 | 2003 | 3044 | 0.100 |
Why?
|
Paraneoplastic Cerebellar Degeneration | 1 | 2011 | 13 | 0.100 |
Why?
|
Histone Deacetylases | 2 | 2007 | 718 | 0.100 |
Why?
|
Herpesvirus 4, Human | 2 | 2016 | 1082 | 0.100 |
Why?
|
Caregivers | 1 | 2024 | 2308 | 0.100 |
Why?
|
DNA-Directed DNA Polymerase | 1 | 2015 | 481 | 0.100 |
Why?
|
Receptor Cross-Talk | 2 | 2009 | 118 | 0.100 |
Why?
|
DNA-Binding Proteins | 4 | 2017 | 9618 | 0.090 |
Why?
|
Mice, Nude | 2 | 2017 | 3631 | 0.090 |
Why?
|
Platelet Count | 2 | 2022 | 787 | 0.090 |
Why?
|
Adjuvants, Immunologic | 2 | 2023 | 999 | 0.090 |
Why?
|
Protein Kinases | 1 | 2018 | 1611 | 0.090 |
Why?
|
Autoantigens | 1 | 2015 | 891 | 0.090 |
Why?
|
Neoplastic Stem Cells | 1 | 2018 | 1356 | 0.090 |
Why?
|
Apoptosis | 4 | 2007 | 9527 | 0.090 |
Why?
|
Exonucleases | 1 | 2010 | 42 | 0.090 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2020 | 3671 | 0.090 |
Why?
|
Immunotherapy | 3 | 2023 | 4756 | 0.090 |
Why?
|
RNA Interference | 3 | 2016 | 2835 | 0.090 |
Why?
|
Peritoneum | 1 | 2011 | 231 | 0.090 |
Why?
|
Expert Systems | 1 | 2010 | 79 | 0.090 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2019 | 3621 | 0.090 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2014 | 592 | 0.080 |
Why?
|
Pelvis | 1 | 2014 | 738 | 0.080 |
Why?
|
Fluorescent Antibody Technique | 1 | 2014 | 2474 | 0.080 |
Why?
|
Cohort Studies | 4 | 2021 | 41808 | 0.080 |
Why?
|
Molecular Targeted Therapy | 3 | 2015 | 2830 | 0.080 |
Why?
|
Genes, Neoplasm | 1 | 2011 | 371 | 0.080 |
Why?
|
Databases, Nucleic Acid | 1 | 2010 | 204 | 0.080 |
Why?
|
RNA, Neoplasm | 2 | 2009 | 751 | 0.080 |
Why?
|
Cell Proliferation | 4 | 2014 | 10486 | 0.080 |
Why?
|
Evolution, Molecular | 1 | 2017 | 1894 | 0.080 |
Why?
|
Receptors, Growth Factor | 1 | 2009 | 326 | 0.080 |
Why?
|
Granzymes | 1 | 2010 | 278 | 0.080 |
Why?
|
Omentum | 2 | 2019 | 168 | 0.080 |
Why?
|
Laryngeal Neoplasms | 1 | 2012 | 514 | 0.070 |
Why?
|
Gene Targeting | 1 | 2011 | 841 | 0.070 |
Why?
|
Cluster Analysis | 2 | 2016 | 2732 | 0.070 |
Why?
|
Acetylation | 2 | 2007 | 1056 | 0.070 |
Why?
|
Farnesyltranstransferase | 1 | 2007 | 71 | 0.070 |
Why?
|
Mice | 10 | 2024 | 82072 | 0.070 |
Why?
|
Anti-Bacterial Agents | 1 | 2006 | 7478 | 0.070 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2011 | 618 | 0.070 |
Why?
|
Receptors, Erythropoietin | 1 | 2007 | 144 | 0.070 |
Why?
|
Receptor, erbB-3 | 1 | 2008 | 143 | 0.070 |
Why?
|
Survival Analysis | 3 | 2019 | 10115 | 0.070 |
Why?
|
Pharmacogenetics | 1 | 2011 | 683 | 0.070 |
Why?
|
Antigens, Differentiation | 1 | 2010 | 921 | 0.070 |
Why?
|
Small Ubiquitin-Related Modifier Proteins | 1 | 2007 | 68 | 0.070 |
Why?
|
Erythrocyte Inclusions | 1 | 2006 | 4 | 0.070 |
Why?
|
Brachytherapy | 1 | 2014 | 1224 | 0.070 |
Why?
|
Disease Progression | 4 | 2022 | 13674 | 0.070 |
Why?
|
Hysterectomy | 1 | 2012 | 866 | 0.070 |
Why?
|
Blotting, Western | 1 | 2014 | 5033 | 0.070 |
Why?
|
Risk Factors | 9 | 2023 | 74976 | 0.070 |
Why?
|
Retinoids | 1 | 2007 | 99 | 0.070 |
Why?
|
RNA, Small Interfering | 2 | 2016 | 3433 | 0.070 |
Why?
|
Macrophages | 2 | 2020 | 5801 | 0.070 |
Why?
|
p300-CBP Transcription Factors | 1 | 2007 | 148 | 0.070 |
Why?
|
BCG Vaccine | 1 | 2009 | 383 | 0.060 |
Why?
|
Outpatients | 1 | 2014 | 1603 | 0.060 |
Why?
|
Structure-Activity Relationship | 1 | 2011 | 3057 | 0.060 |
Why?
|
STAT3 Transcription Factor | 2 | 2023 | 874 | 0.060 |
Why?
|
Recurrence | 2 | 2023 | 8513 | 0.060 |
Why?
|
Metabolic Networks and Pathways | 1 | 2010 | 800 | 0.060 |
Why?
|
Fibroblasts | 3 | 2020 | 4179 | 0.060 |
Why?
|
Epigenesis, Genetic | 3 | 2007 | 3836 | 0.060 |
Why?
|
Histone Acetyltransferases | 1 | 2007 | 335 | 0.060 |
Why?
|
Naproxen | 1 | 2005 | 101 | 0.060 |
Why?
|
Antibodies, Protozoan | 1 | 2006 | 251 | 0.060 |
Why?
|
Drug Design | 2 | 2007 | 1046 | 0.060 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2011 | 799 | 0.060 |
Why?
|
Propionates | 1 | 2005 | 180 | 0.060 |
Why?
|
Infarction, Posterior Cerebral Artery | 1 | 2004 | 15 | 0.060 |
Why?
|
Doping in Sports | 1 | 2005 | 62 | 0.060 |
Why?
|
Life Style | 1 | 2016 | 3931 | 0.060 |
Why?
|
Protein Binding | 3 | 2018 | 9344 | 0.060 |
Why?
|
Cell Differentiation | 4 | 2016 | 11684 | 0.060 |
Why?
|
Exercise | 1 | 2021 | 5954 | 0.060 |
Why?
|
Dendritic Cells | 2 | 2018 | 2748 | 0.060 |
Why?
|
Cell Survival | 1 | 2014 | 5793 | 0.060 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2012 | 4064 | 0.060 |
Why?
|
Killer Cells, Natural | 2 | 2024 | 2211 | 0.060 |
Why?
|
Sarcoma, Kaposi | 1 | 2007 | 375 | 0.050 |
Why?
|
False Positive Reactions | 1 | 2006 | 963 | 0.050 |
Why?
|
Telomerase | 1 | 2009 | 753 | 0.050 |
Why?
|
Case-Control Studies | 1 | 2021 | 22296 | 0.050 |
Why?
|
Flow Cytometry | 1 | 2014 | 5906 | 0.050 |
Why?
|
Drug Interactions | 1 | 2008 | 1418 | 0.050 |
Why?
|
Proportional Hazards Models | 3 | 2016 | 12562 | 0.050 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2005 | 319 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2023 | 6982 | 0.050 |
Why?
|
Follow-Up Studies | 3 | 2020 | 39394 | 0.050 |
Why?
|
Infectious Mononucleosis | 1 | 2003 | 133 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7460 | 0.050 |
Why?
|
Estrogen Receptor beta | 1 | 2003 | 171 | 0.050 |
Why?
|
Prospective Studies | 3 | 2023 | 54962 | 0.050 |
Why?
|
Mice, SCID | 2 | 2018 | 2631 | 0.050 |
Why?
|
Substance Abuse Detection | 1 | 2005 | 301 | 0.050 |
Why?
|
Heat-Shock Proteins | 2 | 2004 | 797 | 0.050 |
Why?
|
Multivariate Analysis | 2 | 2016 | 12095 | 0.050 |
Why?
|
Angiogenesis Inhibitors | 1 | 2012 | 2059 | 0.050 |
Why?
|
Polyethylene Glycols | 2 | 2020 | 1197 | 0.050 |
Why?
|
Nuclear Proteins | 1 | 2016 | 5804 | 0.050 |
Why?
|
Adenosine Diphosphate | 1 | 2022 | 422 | 0.050 |
Why?
|
Molecular Structure | 1 | 2006 | 1885 | 0.050 |
Why?
|
Ubiquitin | 1 | 2006 | 843 | 0.050 |
Why?
|
Cell Division | 1 | 2009 | 4478 | 0.050 |
Why?
|
Stromal Cells | 1 | 2007 | 1337 | 0.050 |
Why?
|
Immunoglobulin M | 1 | 2006 | 1528 | 0.050 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2022 | 300 | 0.050 |
Why?
|
Soft Tissue Neoplasms | 1 | 2010 | 1166 | 0.050 |
Why?
|
Protein Transport | 1 | 2007 | 1956 | 0.050 |
Why?
|
Phenotype | 2 | 2016 | 16731 | 0.040 |
Why?
|
In Situ Hybridization | 2 | 2016 | 1904 | 0.040 |
Why?
|
Receptors, Cell Surface | 1 | 2010 | 2820 | 0.040 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2022 | 432 | 0.040 |
Why?
|
Genetic Variation | 1 | 2015 | 6611 | 0.040 |
Why?
|
Janus Kinase 1 | 1 | 2020 | 108 | 0.040 |
Why?
|
Sequence Analysis, DNA | 1 | 2011 | 4785 | 0.040 |
Why?
|
HIV Infections | 1 | 2006 | 17591 | 0.040 |
Why?
|
Self Efficacy | 1 | 2024 | 643 | 0.040 |
Why?
|
Reproducibility of Results | 3 | 2017 | 20245 | 0.040 |
Why?
|
Male | 11 | 2023 | 365203 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 2022 | 794 | 0.040 |
Why?
|
Laparoscopy | 1 | 2011 | 2055 | 0.040 |
Why?
|
Adnexa Uteri | 1 | 2019 | 40 | 0.040 |
Why?
|
DNA Copy Number Variations | 2 | 2020 | 2055 | 0.040 |
Why?
|
Retrospective Studies | 6 | 2022 | 81903 | 0.040 |
Why?
|
Gastric Mucosa | 1 | 2002 | 602 | 0.040 |
Why?
|
Antigens, CD | 1 | 2010 | 4032 | 0.040 |
Why?
|
Diamines | 1 | 2019 | 60 | 0.040 |
Why?
|
Pilot Projects | 2 | 2024 | 8748 | 0.040 |
Why?
|
Models, Biological | 4 | 2007 | 9499 | 0.040 |
Why?
|
Lymphatic Metastasis | 2 | 2004 | 2916 | 0.040 |
Why?
|
Sequence Analysis, RNA | 2 | 2020 | 2041 | 0.040 |
Why?
|
HEK293 Cells | 2 | 2018 | 4290 | 0.040 |
Why?
|
Cerebral Angiography | 1 | 2004 | 1272 | 0.040 |
Why?
|
Natural Killer T-Cells | 1 | 2022 | 318 | 0.040 |
Why?
|
Forecasting | 1 | 2007 | 2945 | 0.040 |
Why?
|
Neoplasm, Residual | 1 | 2023 | 1019 | 0.040 |
Why?
|
Online Systems | 1 | 2019 | 182 | 0.040 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2007 | 1903 | 0.040 |
Why?
|
Ovariectomy | 1 | 2020 | 613 | 0.040 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2007 | 2203 | 0.040 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2019 | 330 | 0.040 |
Why?
|
Gold | 1 | 2022 | 488 | 0.040 |
Why?
|
Decision Making | 1 | 2012 | 3953 | 0.040 |
Why?
|
Neurodegenerative Diseases | 1 | 2007 | 1094 | 0.040 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2020 | 2960 | 0.040 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2019 | 252 | 0.040 |
Why?
|
Recombinant Proteins | 1 | 2007 | 6512 | 0.040 |
Why?
|
Statistics, Nonparametric | 1 | 2003 | 2862 | 0.040 |
Why?
|
Receptors, Androgen | 1 | 2004 | 1091 | 0.040 |
Why?
|
Chromosome Deletion | 1 | 2022 | 1390 | 0.030 |
Why?
|
Proto-Oncogene Proteins | 1 | 2009 | 4528 | 0.030 |
Why?
|
Advance Care Planning | 1 | 2024 | 698 | 0.030 |
Why?
|
Adolescent | 3 | 2020 | 89244 | 0.030 |
Why?
|
Morpholines | 1 | 2019 | 584 | 0.030 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2024 | 957 | 0.030 |
Why?
|
Organ Culture Techniques | 1 | 2018 | 796 | 0.030 |
Why?
|
Receptors, Complement 3d | 1 | 2016 | 117 | 0.030 |
Why?
|
Aminopyridines | 1 | 2019 | 580 | 0.030 |
Why?
|
Predictive Value of Tests | 3 | 2020 | 15471 | 0.030 |
Why?
|
Young Adult | 2 | 2020 | 60131 | 0.030 |
Why?
|
Precancerous Conditions | 1 | 2002 | 985 | 0.030 |
Why?
|
Antigens, Nuclear | 1 | 2016 | 183 | 0.030 |
Why?
|
Lymphocytes | 1 | 2003 | 2614 | 0.030 |
Why?
|
Microtubule-Associated Proteins | 1 | 2020 | 1074 | 0.030 |
Why?
|
Embryo Loss | 1 | 2015 | 55 | 0.030 |
Why?
|
Viral Matrix Proteins | 1 | 2016 | 193 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2018 | 2018 | 0.030 |
Why?
|
Methylation | 1 | 2017 | 1078 | 0.030 |
Why?
|
Microscopy, Fluorescence | 1 | 2022 | 2635 | 0.030 |
Why?
|
Cell Nucleus | 1 | 2023 | 2885 | 0.030 |
Why?
|
Blood Platelets | 1 | 2005 | 2479 | 0.030 |
Why?
|
DNA Repair Enzymes | 1 | 2016 | 346 | 0.030 |
Why?
|
Lipopolysaccharides | 1 | 2022 | 2222 | 0.030 |
Why?
|
Fanconi Anemia Complementation Group D2 Protein | 1 | 2015 | 148 | 0.030 |
Why?
|
Immunoglobulin G | 1 | 2006 | 4568 | 0.030 |
Why?
|
Education, Medical | 1 | 2006 | 1742 | 0.030 |
Why?
|
Aging | 1 | 2013 | 8745 | 0.030 |
Why?
|
Base Sequence | 2 | 2016 | 12430 | 0.030 |
Why?
|
Vinca Alkaloids | 1 | 2013 | 36 | 0.030 |
Why?
|
Fluorescent Dyes | 1 | 2022 | 1933 | 0.030 |
Why?
|
Antibodies | 1 | 2022 | 2422 | 0.030 |
Why?
|
Pyridones | 1 | 2019 | 819 | 0.030 |
Why?
|
Mice, Inbred C57BL | 2 | 2024 | 22379 | 0.030 |
Why?
|
HSP27 Heat-Shock Proteins | 2 | 2004 | 67 | 0.030 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2024 | 1756 | 0.030 |
Why?
|
Oligonucleotides, Antisense | 1 | 2016 | 461 | 0.030 |
Why?
|
Fallopian Tubes | 1 | 2013 | 179 | 0.030 |
Why?
|
Immunoblotting | 1 | 2016 | 1647 | 0.030 |
Why?
|
Observer Variation | 1 | 2019 | 2623 | 0.030 |
Why?
|
Cerebral Hemorrhage | 1 | 2004 | 2660 | 0.030 |
Why?
|
Head and Neck Neoplasms | 1 | 2007 | 2931 | 0.030 |
Why?
|
Amino Acid Motifs | 1 | 2015 | 930 | 0.030 |
Why?
|
Monocytes | 1 | 2022 | 2603 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2019 | 1625 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2010 | 10276 | 0.020 |
Why?
|
Immunity, Innate | 1 | 2024 | 3080 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 2018 | 1780 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2016 | 1839 | 0.020 |
Why?
|
Gene Dosage | 1 | 2016 | 1222 | 0.020 |
Why?
|
Brain Neoplasms | 1 | 2013 | 9213 | 0.020 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2018 | 1803 | 0.020 |
Why?
|
Migraine Disorders | 1 | 2004 | 1713 | 0.020 |
Why?
|
Sequence Alignment | 1 | 2016 | 2179 | 0.020 |
Why?
|
Ki-67 Antigen | 1 | 2013 | 628 | 0.020 |
Why?
|
HeLa Cells | 1 | 2017 | 3076 | 0.020 |
Why?
|
Gene Library | 1 | 2014 | 1062 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 3 | 2022 | 18068 | 0.020 |
Why?
|
Infusions, Parenteral | 1 | 2011 | 396 | 0.020 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2011 | 109 | 0.020 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2016 | 755 | 0.020 |
Why?
|
Chronic Disease | 1 | 2006 | 9384 | 0.020 |
Why?
|
Motivation | 1 | 2021 | 2025 | 0.020 |
Why?
|
DNA Helicases | 1 | 2016 | 854 | 0.020 |
Why?
|
Transcriptional Activation | 2 | 2007 | 1750 | 0.020 |
Why?
|
Paraffin Embedding | 1 | 2012 | 306 | 0.020 |
Why?
|
Tissue Fixation | 1 | 2012 | 245 | 0.020 |
Why?
|
Nausea | 1 | 2013 | 682 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2019 | 2460 | 0.020 |
Why?
|
Formaldehyde | 1 | 2012 | 361 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2018 | 3629 | 0.020 |
Why?
|
Nanoparticles | 1 | 2022 | 1989 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2024 | 3235 | 0.020 |
Why?
|
Diplopia | 1 | 2011 | 217 | 0.020 |
Why?
|
Macaca mulatta | 1 | 2017 | 2365 | 0.020 |
Why?
|
Genes, T-Cell Receptor beta | 1 | 2010 | 70 | 0.020 |
Why?
|
Prevalence | 1 | 2006 | 15879 | 0.020 |
Why?
|
Cell Death | 1 | 2015 | 1682 | 0.020 |
Why?
|
Cell Fusion | 1 | 2010 | 294 | 0.020 |
Why?
|
Ataxia | 1 | 2011 | 307 | 0.020 |
Why?
|
DNA, Viral | 1 | 2016 | 2205 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2022 | 4413 | 0.020 |
Why?
|
Embryonic Stem Cells | 1 | 2016 | 1251 | 0.020 |
Why?
|
Retinal Dehydrogenase | 1 | 2009 | 78 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2013 | 1608 | 0.020 |
Why?
|
Epithelium | 1 | 2013 | 1607 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2024 | 14484 | 0.020 |
Why?
|
Catheters, Indwelling | 1 | 2011 | 436 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2019 | 2986 | 0.020 |
Why?
|
Benzimidazoles | 1 | 2014 | 864 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2016 | 1667 | 0.020 |
Why?
|
Multiple Myeloma | 1 | 2006 | 5196 | 0.020 |
Why?
|
Molecular Chaperones | 2 | 2004 | 763 | 0.020 |
Why?
|
Biopsy | 1 | 2020 | 6805 | 0.020 |
Why?
|
Patient Selection | 1 | 2020 | 4265 | 0.020 |
Why?
|
Aldehyde Dehydrogenase | 1 | 2009 | 146 | 0.020 |
Why?
|
Substance-Related Disorders | 1 | 2005 | 4423 | 0.020 |
Why?
|
Proteomics | 1 | 2022 | 3914 | 0.020 |
Why?
|
Oligopeptides | 1 | 2013 | 1194 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2016 | 2395 | 0.020 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2010 | 640 | 0.020 |
Why?
|
Genotype | 1 | 2022 | 13048 | 0.020 |
Why?
|
Aptamers, Peptide | 1 | 2007 | 28 | 0.020 |
Why?
|
Algorithms | 2 | 2022 | 14201 | 0.020 |
Why?
|
Estrogen Receptor Modulators | 1 | 2007 | 58 | 0.020 |
Why?
|
Folic Acid | 1 | 2013 | 1338 | 0.020 |
Why?
|
Cell Cycle | 1 | 2015 | 2937 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2017 | 2649 | 0.020 |
Why?
|
Clone Cells | 1 | 2010 | 1670 | 0.020 |
Why?
|
Fatigue | 1 | 2013 | 1557 | 0.020 |
Why?
|
Receptors, Retinoic Acid | 1 | 2007 | 229 | 0.020 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2010 | 1356 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2014 | 1204 | 0.020 |
Why?
|
Indoles | 1 | 2014 | 1836 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2014 | 1970 | 0.020 |
Why?
|
Janus Kinases | 1 | 2007 | 253 | 0.020 |
Why?
|
Urinary Bladder | 1 | 2011 | 1162 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2009 | 567 | 0.020 |
Why?
|
Dimerization | 1 | 2007 | 886 | 0.020 |
Why?
|
Mucin-1 | 1 | 2010 | 539 | 0.020 |
Why?
|
Muscle Cells | 1 | 2005 | 195 | 0.010 |
Why?
|
Antigen Presentation | 1 | 2010 | 1252 | 0.010 |
Why?
|
Isoenzymes | 1 | 2009 | 1687 | 0.010 |
Why?
|
Epithelial Cells | 1 | 2016 | 3702 | 0.010 |
Why?
|
Oligonucleotides | 1 | 2007 | 563 | 0.010 |
Why?
|
Cell Line | 1 | 2017 | 15604 | 0.010 |
Why?
|
Carrier Proteins | 1 | 2016 | 4939 | 0.010 |
Why?
|
United States | 2 | 2022 | 73186 | 0.010 |
Why?
|
Autoantibodies | 1 | 2011 | 2120 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2017 | 14752 | 0.010 |
Why?
|
Cancer Vaccines | 1 | 2010 | 1043 | 0.010 |
Why?
|
Incidence | 2 | 2014 | 21547 | 0.010 |
Why?
|
Reference Values | 1 | 2009 | 4940 | 0.010 |
Why?
|
Metaplasia | 1 | 2002 | 326 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2010 | 3163 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2014 | 17629 | 0.010 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2005 | 1169 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2016 | 19023 | 0.010 |
Why?
|
Gene Expression | 1 | 2013 | 7603 | 0.010 |
Why?
|
Computational Biology | 1 | 2012 | 3562 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2007 | 3775 | 0.010 |
Why?
|
Pleural Effusion | 1 | 2003 | 345 | 0.010 |
Why?
|
Ultraviolet Rays | 1 | 2005 | 1104 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 2010 | 4926 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2010 | 3518 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2018 | 18354 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2014 | 12806 | 0.010 |
Why?
|
Receptors, Progesterone | 1 | 2004 | 1159 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2017 | 11932 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2010 | 5505 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 2011 | 4413 | 0.010 |
Why?
|
Time Factors | 1 | 2020 | 40261 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2004 | 36854 | 0.010 |
Why?
|
Drug Delivery Systems | 1 | 2008 | 2238 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2012 | 14794 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2007 | 7609 | 0.010 |
Why?
|
DNA Methylation | 1 | 2007 | 4432 | 0.010 |
Why?
|
Endothelial Cells | 1 | 2005 | 3592 | 0.010 |
Why?
|
Radiography | 1 | 2003 | 6991 | 0.010 |
Why?
|
Antibodies, Viral | 1 | 2003 | 3215 | 0.010 |
Why?
|
Genomics | 1 | 2005 | 5928 | 0.000 |
Why?
|